{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:25:05Z","timestamp":1783398305734,"version":"3.54.6"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40259-019-00361-6","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T10:02:54Z","timestamp":1559815374000},"page":"391-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis"],"prefix":"10.1007","volume":"33","author":[{"given":"Joel","family":"Reis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Vender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"key":"361_CR1","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/j.1365-2133.2011.10494.x","volume":"165","author":"Y-W Yang","year":"2011","unstructured":"Yang Y-W, Keller JJ, Lin H-C. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol. 2011;165:1037\u201343.","journal-title":"Br J Dermatol."},{"key":"361_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377\u201390.","journal-title":"J Am Acad Dermatol."},{"key":"361_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clindermatol.2007.08.007","volume":"25","author":"JE Gudjonsson","year":"2007","unstructured":"Gudjonsson JE. Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25:535\u201346.","journal-title":"Clin Dermatol."},{"key":"361_CR4","first-page":"848","volume":"13","author":"AA Levin","year":"2014","unstructured":"Levin AA, Gottlieb AB, Au S. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014;13:848\u201353.","journal-title":"J Drugs Dermatol."},{"key":"361_CR5","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201:1605\u201313.","journal-title":"J Immunol."},{"key":"361_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/14712598.2019.1555235","volume":"19","author":"A Silfvast-Kaiser","year":"2019","unstructured":"Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther. 2019;19:45\u201354.","journal-title":"Expert Opin Biol Ther."},{"key":"361_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","volume":"77","author":"KF Baker","year":"2018","unstructured":"Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis? Ann Rheum Dis. 2018;77:175\u201387.","journal-title":"Ann Rheum Dis."},{"key":"361_CR8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/13543784.2016.1187130","volume":"25","author":"T Torres","year":"2016","unstructured":"Torres T, Romanelli M, Chiricozzi A. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016;25:751\u20134.","journal-title":"Expert Opin Investig Drugs."},{"issue":"3","key":"361_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390.","journal-title":"Clin Rev Allergy Immunol."},{"key":"361_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585\u2013600.","journal-title":"Nat Rev Immunol."},{"key":"361_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2017.1292137","volume":"13","author":"L Puig","year":"2017","unstructured":"Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13:525\u201334.","journal-title":"Expert Rev Clin Immunol."},{"key":"361_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cyto.2013.03.014","volume":"62","author":"X Song","year":"2013","unstructured":"Song X, Qian Y. The activation and regulation of IL-17 receptor mediated signaling. Cytokine. 2013;62:175\u201382.","journal-title":"Cytokine."},{"key":"361_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","volume":"160","author":"C Johansen","year":"2009","unstructured":"Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160:319\u201324.","journal-title":"Br J Dermatol."},{"key":"361_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cyto.2013.07.022","volume":"64","author":"C Gu","year":"2013","unstructured":"Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and signaling. Cytokine. 2013;64:477\u201385.","journal-title":"Cytokine."},{"key":"361_CR15","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"NC Brembilla","year":"2018","unstructured":"Brembilla NC, Senra L, Boehncke W-H. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682.","journal-title":"Front Immunol."},{"key":"361_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/jid.2012.194","volume":"133","author":"DA Martin","year":"2013","unstructured":"Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133:17\u201326.","journal-title":"J Invest Dermatol."},{"key":"361_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"BW Kirkham","year":"2014","unstructured":"Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141:133\u201342.","journal-title":"Immunology."},{"key":"361_CR18","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.1074\/jbc.C600322200","volume":"282","author":"AM Akimzhanov","year":"2007","unstructured":"Akimzhanov AM, Yang XO, Dong C. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation. J Biol Chem. 2007;282:5969\u201372.","journal-title":"J Biol Chem."},{"key":"361_CR19","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.4049\/jimmunol.181.4.2799","volume":"181","author":"JF Wright","year":"2008","unstructured":"Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters MJ, et al. The human IL-17F\/IL-17A heterodimeric cytokine signals through the IL-17RA\/IL-17RC receptor complex. J Immunol. 2008;181:2799\u2013805.","journal-title":"J Immunol."},{"key":"361_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nri2586","volume":"9","author":"SL Gaffen","year":"2009","unstructured":"Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556\u201367.","journal-title":"Nat Rev Immunol."},{"key":"361_CR21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1208\/s12248-017-0094-4","volume":"19","author":"C Soderstrom","year":"2017","unstructured":"Soderstrom C, Berstein G, Zhang W, Valdez H, Fitz L, Kuhn M, et al. Ultra-sensitive measurement of IL-17A and IL-17F in psoriasis patient serum and skin. AAPS J. 2017;19:1218\u201322.","journal-title":"AAPS J."},{"key":"361_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/jid.2008.294","volume":"129","author":"H Watanabe","year":"2009","unstructured":"Watanabe H, Kawaguchi M, Fujishima S, Ogura M, Matsukura S, Takeuchi H, et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J Invest Dermatol. 2009;129:650\u20136.","journal-title":"J Invest Dermatol."},{"key":"361_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00403-010-1033-8","volume":"302","author":"S Fujishima","year":"2010","unstructured":"Fujishima S, Watanabe H, Kawaguchi M, Suzuki T, Matsukura S, Homma T, et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res. 2010;302:499\u2013505.","journal-title":"Arch Dermatol Res."},{"key":"361_CR24","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1172\/JCI61862","volume":"122","author":"S Pantelyushin","year":"2012","unstructured":"Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA, et al. Ror\u03b3t+ innate lymphocytes and \u03b3\u03b4 T cells initiate psoriasiform plaque formation in mice. J Clin Invest. 2012;122:2252\u20136.","journal-title":"J Clin Invest."},{"key":"361_CR25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jid.2016.10.024","volume":"137","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Gudjonsson JE, Ward NL. The snowballing literature on imiquimod-induced skin inflammation in mice: a critical appraisal. J Invest Dermatol. 2017;137:546\u20139.","journal-title":"J Invest Dermatol."},{"key":"361_CR26","doi-asserted-by":"crossref","unstructured":"Maroof A, Okoye R, Smallie T, Baeten D, Arche S, Simpson C, et al. Bimekizumab dual inhibition of IL-17A and IL-17F provides evidence of IL-17F contribution to chronic inflammation in disease-relevant cells [abstract no. 1571]. Arthritis Rheumatol. 2017;69 (suppl. 10). https:\/\/acrabstracts.org\/abstract\/bimekizumab-dual-inhibition-of-il-17a-and-il-17f-provides-evidence-of-il-17f-contribution-to-chronic-inflammation-in-disease-relevant-cells\/ . Accessed 1 Mar 2019.","DOI":"10.1136\/annrheumdis-2017-eular.4966"},{"key":"361_CR27","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bcp.13185","volume":"83","author":"S Glatt","year":"2017","unstructured":"Glatt S, Helmer E, Haier B, Strimenopoulou F, Price G, Vajjah P, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83:991\u20131001.","journal-title":"Br J Clin Pharmacol."},{"key":"361_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-018-0888-4","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA. Brodalumab: a review in moderate to severe plaque psoriasis. Drugs. 2018;78:495\u2013504.","journal-title":"Drugs."},{"key":"361_CR29","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2008-08-172767","volume":"113","author":"R Caruso","year":"2009","unstructured":"Caruso R, Stolfi C, Sarra M, Rizzo A, Fantini MC, Pallone F, et al. Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3. Blood. 2009;113:3512\u20139.","journal-title":"Blood."},{"issue":"277\u2013286","key":"361_CR30","first-page":"e10","volume":"79","author":"KA Papp","year":"2018","unstructured":"Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(277\u2013286):e10.","journal-title":"J Am Acad Dermatol."},{"key":"361_CR31","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Papp K, Merola J, Gottlieb A, Cross N, Madden C, et al. Dual neutralization of interleukin (IL)-17A and IL-17F with bimekizumab in moderate-to-severe plaque psoriasis: 60-week results from a randomized, double-blinded, phase 2b extension study [abstract]. American Academy of Dermatology (AAD) Annual Meeting; 1\u20135 Mar 2019; Washington, DC.","DOI":"10.1136\/annrheumdis-2019-eular.4166"},{"key":"361_CR32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523\u201332.","journal-title":"Ann Rheum Dis."},{"key":"361_CR33","unstructured":"UCB. Bimekizumab demonstrates impressive joint and skin responses for psoriatic arthritis patients. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/Bimekizumab-demonstrates-impressive-joint-and-skin-responses-for-psoriatic-arthritis-patients-nbsp . Accessed 17 Oct 2018."},{"key":"361_CR34","doi-asserted-by":"crossref","unstructured":"Ritchlin C, Kavanaugh A, Merola JF, Schett G, Scher J, Warren R, et al. Dual neutralization of IL-17A and IL-17F with bimekizumab in patients with active Psa: results from a 48-week phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study [abstract no. L17]. Arthritis Rheumatol. 2018;70 (suppl 10). https:\/\/acrabstracts.org\/abstract\/dual-neutralization-of-il-17a-and-il-17f-with-bimekizumab-in-patients-with-active-psa-results-from-a-48-week-phase-2b-randomized-double-blind-placebo-controlled-dose-ranging-study\/ . Accessed 17 Mar 2019.","DOI":"10.1136\/annrheumdis-2019-eular.4883"},{"key":"361_CR35","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Gensler LS, Deodhar A, Baraliakos X, Poddubnyy D, Farmer MK, et al. Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study [abstract no. LB0001]. Ann Rheum Dis. 2018;77:70. http:\/\/ard.bmj.com\/lookup\/doi\/10.1136\/annrheumdis-2018-eular.7889 . Accessed 17 Mar 2019.","DOI":"10.1136\/annrheumdis-2018-eular.7889"},{"key":"361_CR36","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/rheumatology\/key312","volume":"58","author":"A Khatri","year":"2019","unstructured":"Khatri A, Kl\u00fcnder B, Peloso PM, Othman AA. Exposure\u2013response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis. Rheumatology. 2019;58:352\u201360.","journal-title":"Rheumatology."},{"key":"361_CR37","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/rheumatology\/key173","volume":"57","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Weinblatt ME, Mease PJ, Aelion JA, Peloso PM, Chen K, et al. Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology. 2018;57:1972\u201381.","journal-title":"Rheumatology."},{"key":"361_CR38","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/art.40580","volume":"70","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Weinblatt ME, Aelion JA, Mansikka HT, Peloso PM, Chen K, et al. ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17A, in patients with rheumatoid arthritis with an inadequate response to methotrexate: a randomized, double-blind study. Arthritis Rheumatol. 2018;70:1710\u201320.","journal-title":"Arthritis Rheumatol."},{"key":"361_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/14728214.2018.1445719","volume":"23","author":"J Rademacher","year":"2018","unstructured":"Rademacher J, Poddubnyy D. Emerging drugs for the treatment of axial spondyloarthritis. Expert Opin Emerg Drugs. 2018;23:83\u201396.","journal-title":"Expert Opin Emerg Drugs."},{"key":"361_CR40","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534\u201348.","journal-title":"N Engl J Med."},{"key":"361_CR41","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, \u00d8stergaard M, Wei JC-C, Sieper J, J\u00e4rvinen P, Tam L-S, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77:1295\u2013302.","journal-title":"Ann Rheum Dis."},{"key":"361_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","volume":"30","author":"H Ishigame","year":"2009","unstructured":"Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity. 2009;30:108\u201319.","journal-title":"Immunity."},{"key":"361_CR43","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1084\/jem.20071978","volume":"205","author":"XO Yang","year":"2008","unstructured":"Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205:1063\u201375.","journal-title":"J Exp Med."},{"issue":"9","key":"361_CR44","first-page":"e60","volume":"2","author":"W Jin","year":"2013","unstructured":"Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2013;2(9):e60.","journal-title":"Emerg Microbes Infect."},{"key":"361_CR45","first-page":"202","volume":"7","author":"Z Babaloo","year":"2010","unstructured":"Babaloo Z, Babaie F, Farhoodi M, Aliparasti MR, Baradaran B, Almasi S, et al. Interleukin-17A and interleukin-17F mRNA expression in peripheral blood mononuclear cells of patients with multiple sclerosis. Iran J Immunol. 2010;7:202\u20139.","journal-title":"Iran J Immunol."},{"key":"361_CR46","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1097\/MIB.0b013e318286fa1c","volume":"19","author":"EG Wedebye Schmidt","year":"2013","unstructured":"Wedebye Schmidt EG, Larsen HL, Kristensen NN, Poulsen SS, Lynge Pedersen AM, Claesson MH, et al. TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflamm Bowel Dis. 2013;19:1567\u201376.","journal-title":"Inflamm Bowel Dis."},{"key":"361_CR47","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jacbts.2016.07.009","volume":"1","author":"MA Saleh","year":"2016","unstructured":"Saleh MA, Norlander AE, Madhur MS. Inhibition of interleukin-17A, but not interleukin-17F, signaling lowers blood pressure, and reduces end-organ inflammation in angiotensin II\u2013induced hypertension. JACC Basic Transl Sci. 2016;1:606\u201316.","journal-title":"JACC Basic Transl Sci."},{"key":"361_CR48","doi-asserted-by":"publisher","first-page":"e34959","DOI":"10.1371\/journal.pone.0034959","volume":"7","author":"Z Tong","year":"2012","unstructured":"Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One. 2012;7:e34959.","journal-title":"PLoS One."},{"key":"361_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cyto.2015.09.011","volume":"89","author":"X Qian","year":"2017","unstructured":"Qian X, Chen H, Wu X, Hu L, Huang Q, Jin Y. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine. 2017;89:34\u201344.","journal-title":"Cytokine."},{"key":"361_CR50","unstructured":"UCB Biopharma S.P.R.L. A study to evaluate the efficacy and safety of bimekizumab in the treatment of subjects with active psoriatic arthritis (BE COMPLETE) [ClinicalTrials.gov identifier NCT03896581]. National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov . Accessed 30 May 2019."},{"key":"361_CR51","unstructured":"UCB Biopharma S.P.R.L. A study to test the efficacy and safety of bimekizumab in the treatment of subjects with active psoriatic arthritis (BE OPTIMAL) [ClinicalTrials.gov identifier NCT03895203]. National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov . Accessed 30 May 2019."},{"key":"361_CR52","unstructured":"UCB Biopharma S.P.R.L. A study to evaluate the efficacy and safety of bimekizumab in subjects with active ankylosing spondylitis (BE MOBILE 2) [ClinicalTrials.gov identifier NCT03928743]. National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov . Accessed 30 May 2019."},{"key":"361_CR53","unstructured":"UCB Biopharma S.P.R.L. A study to evaluate the efficacy and safety of bimekizumab in subjects with active nonradiographic axial spondyloarthritis (BE MOBILE 1) [ClinicalTrials.gov identifier NCT03928704]. National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov . Accessed 30 May 2019."},{"key":"361_CR54","unstructured":"UCB Biopharma S.P.R.L. A study to evaluate the efficacy and safety of bimekizumab compared to placebo and an active comparator in adult subjects with moderate to severe chronic plaque psoriasis (BE VIVID) [ClinicalTrials.gov identifier NCT03370133]. National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov . Accessed 30 May 2019."},{"key":"361_CR55","unstructured":"UCB Biopharma S.P.R.L. A study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (BE SURE) [ClinicalTrials.gov identifier NCT03412747]. National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov . Accessed 30 May 2019."},{"key":"361_CR56","unstructured":"UCB Biopharma S.P.R.L. A study to evaluate the efficacy and safety of bimekizumab compared to an active comparator in adult subjects with moderate to severe chronic plaque psoriasis (BE RADIANT) [ClinicalTrials.gov identifier NCT03536884]. National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov . Accessed 30 May 2019."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00361-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-019-00361-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00361-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T17:44:04Z","timestamp":1663609444000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-019-00361-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1007\/s40259-019-00361-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,6]]},"assertion":[{"value":"6 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received that was directly related to this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Joel Reis has no conflict of interest. Ron Vender has participated in clinical trials, and has received honoraria for acting as a consultant and\/or as a speaker at events sponsored by AbbVie, Amgen, Boehringer Ingelheim, Celgene, Galderma, GSK, Janssen, Leo-Pharma, Eli-Lilly, MSD, Novartis, UCB, and Pfizer. Tiago Torres has participated in clinical trials, and has received honoraria for acting as a consultant and\/or as a speaker at events sponsored by AbbVie, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo-Pharma, Eli-Lilly, MSD, Novartis, Pfizer, and Sandoz.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}